Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 855-861

  Derian, Claudia K ^a   Damiano, Bruce P ^a   Addo, Michael F ^a   Darrow, Andrew L ^a   D'Andrea, Michael R ^a   Nedelman, Mark ^b   Zhang, Han Cheng ^a   Maryanoff, Bruce E ^a   Andrade Gordon, Patricia ^a  

^a J W Johnson Pharmaceutical Res I   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD61 ANTIGEN; FIBRINOGEN; N [3 AMINO 1 [[(PHENYLMETHYL)AMINO]CARBONYL]PROPYL] ALPHA [[[[1 (2,6 DICHLOROPHENYL)METHYL] 3 (1 PYRROLIDINYLMETHYL) 1H INDAZOL 6 YL]AMINO]CARBONYL]AMINO 3,4 DIFLUOROBENZENEPROPANAMIDE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; RWJ 58259; THROMBIN; THROMBIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CAROTID ARTERY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MONKEY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; THROMBUS;

ANIMALS; CAROTID ARTERY, COMMON; FEMALE; INDAZOLES; MACACA FASCICULARIS; MALE; PLATELET AGGREGATION; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; THROMBOSIS; UREA;

EID: 0037310962     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042663     Document Type: Article

References (38)

1. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang H-C, Addo MF, Cheung W-M, Damiano BP, D'Andrea MR, Darrow AL, De Garavilla L, et al. (2001) Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298:34-42.
2. Badimon L, Meyer BJ, and Badimon JJ (1994) Thrombin in arterial thrombosis. Haemostasis 24:69-80.
3. Bates SM and Weitz JI (1998) Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82:12P-18P.
4. Bellinger DA, Williams JK, Adams MR, Honore EK, and Bender DE (1998) Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model. Arterioscler Thromb Vasc Biol 18:92-99.
5. Chesebro JH, Webster MW, Zoldhelyi P, Roche PC, Badimon L, and Badimon JJ (1992) Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. Circulation 86:100-110.
6. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, and Coughlin SR (1996) Role of the thrombin receptor in development and evidence for a second receptor. Nature (Lond) 381:516-519.
7. Connolly TM, Condra C, Feng D-M, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, and Gould RJ (1994) Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 72:627-633.
8. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng D-M, Nutt RF, Shafer JA, Gould RJ, and Connolly TM (1995) An antibody against the exo-site of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91:2961-2971.
9. Covic L, Singh C, Smith H, and Kuliopulos A (2002) Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak Syndrome. Thromb Haemost 87:722-727.
10. D'Andrea MR, Derian CK, Santulli RJ, and Andrade-Gordon P (2001) Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign and malignant human tissues. Am J Pathol 158:2031-2041.
11. Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, and Andrade-Gordon P (1996) Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 76:860-866.
12. Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, and Andrade-Gordon P (1995) Species differences in platelet responses to thrombin and SFLLRN. Receptormediated calcium mobilization and aggregation and regulation by protein kinases. Thromb Res 78:505-519.
13. Fenton JW, 2nd, Ofosu FA, Brezniak DV, and Hassouna HI (1993) Understanding thrombin and hemostasis. Hematol/Oncol Clinics N Am 7:1107-1119.
14. Gallo R, Chesebro JH, and Badimon JJ (1999) Treatment of unstable angina: role of antithrombotic therapy. Thromb Res 95:V15-V31.
15. Harker LA, Hanson SR, and Runge MS (1995) Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 75:12B-17B.
16. Hasan AAK, Amenta S, and Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94:517-528.
17. Hasan AAK, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR, and Schmaier AH (1999) Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemost 82:1182-1187.
18. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, and Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879-887.
19. Kahn ML, Zheng Y-W, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, and Coughlin SR (1998) A dual thrombin receptor system for platelet activation. Nature (Lond) 394:690-694.
20. Kontny F (1997) Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol 80:55E-60E.
21. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, and Saldeen TGP (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31:345-351.
22. Nakanishi-Matsui M, Zheng Y-W, Sulciner DJ, Weiss EJ, Ludeman MJ, and Coughlin SR (2000) PAR3 is a cofactor for PAR4 activation by thrombin. Nature (Lond) 404:609-613.
23. Pakala R, Liang CT, and Benedict CR (2000) Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor. Thromb Res 100:89-96.
24. Rebello SS, Miller BV, Basler GC, and Lucchesi BR (1997) CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 29:240-249.
25. Rote WE, Davis JH, Mousa SA, Reilly TM, and Lucchesi BR (1994) Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol 23:681-689.
26. Sambrano GR, Weiss EJ, Zheng YW, Huang W, and Coughlin SR (2001) Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature (Lond) 413:74-78.
27. Schmidt VA, Nierman WC, Maglott R, Cupit LD, Moskowitz KA, Wainer JA, and Bahou WF (1998) The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 273:15061-15068.
28. Sudo Y, Kilgore KS, and Lucchesi BR (1995) Monoclonal antibody [7E3 F(ab′)2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharmacol 26:241-250.
29. Sudo YJ and Lucchesi BR (1996) Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 27:545-555.
30. Toombs CF, Degraaf GL, Martin JP, Geng JG, Anderson DC, and Shebuski RJ (1995) Pretreatment with a blocking monoclonal antibody to p-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharmacol Exp Ther 275:941-949.
31. Vu TKH, Hung DT, Wheaton VI, and Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068.
32. Weiss EJ, Hamilton JR, Lease KE, and Coughlin SR (2002) Protection against thrombosis in mice lacking PAR3. Blood 100:3240-3244.
33. Weitz JI and Buller HR (2002) Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105:1004-1011.
34. Weksler BB (2000) Antiplatelet agents in stroke prevention combination therapy: present and future. Cerebrovasc Dis 10:41-48.
35. White HD (1999) Newer antiplatelet agents in acute coronary syndromes. Am Heart J 138:S570-S576.
36. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, and Foster DC (1998) Cloning and characterization of human proteaseactivated receptor 4. Proc Natl Acad Sci USA 95:6642-6646.
37. Zhang, H-C, Derian CK, Hoekstra WJ, McComsey DF, White KB, Addo MF, Andrade-Gordon P, Eckardt AJ, Oksenberg D, Reynolds EE, et al. (2001) Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists. Potent, selective peptide-mimetics based on indole and indazole templates. J Med Chem 44:1021-1024.
38. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, and Chesebro JH (1994) Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 90:2671-2678.